
Last updated: 2026-10-08 13:52:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Acrivon Therapeutics, Inc. (ACRV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.81, with a market capitalization of $79.71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.27 to $3.56. This page covers its latest market performance, valuation, price trends and company information.
$79.71M | |
$1.89 | |
$25.47 | |
$1.05 | |
$1.88 | |
36.28K | |
355.64K | |
-- | |
$3.56 | |
$1.27 | |
-- | |
-- |
Acrivon Therapeutics, Inc. (ACRV) is currently trading at $1.81 as of 2026-10-08 13:51:00, down 3.72% ($0.07) from the previous close of $1.88
During today's regular trading session, ACRV has traded between $1.05 and $25.47, with a trading volume of 36.28K shares. The current price is near the lower end of today's range.
Over the past seven days, Acrivon Therapeutics, Inc. (ACRV) moved from $2.08 to $1.81, representing a decline of 12.98% ($0.27).
The stock traded between $1.81 and $2.16 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 239.43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.6%
ACRV is currently trading at $1.81, placing it 23.6% of the way from its 52-week low of $1.27 to its 52-week high of $3.56. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acrivon Therapeutics, Inc. (ACRV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.